TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07463807: Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With

Sponsor: National Cancer Institute (NCI) · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 162 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07463807 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07463807 Rescue Dossier →